Recentin headed to phase III in first-line colon ca

Based on Independent Data Monitoring Committee review of three phase II trials, AstraZeneca’s HORIZON III phase II/III study of its antiangiogenesis agent Recentin will progress directly into phase III. The study is a head-to-head comparison of first-line Recentin (cediranib, AZD2171) plus FOXFOX vs bevacizumab(Drug information on bevacizumab) (Avastin) plus FOLFOX in patients with metastatic colorectal cancer.

Recentin is a highly potent and selective VEGF signaling inhibitor that inhibits all three VEGF receptors, particularly VEGFR-2, the predominant receptor through which VEGF exerts its effects on angiogenesis, the company said in a press release. The dose for the phase III trial is 20 mg/d orally.

The company further announced that the BR24 phase II/III study of Recentin at 30 mg/d in first-line non-small-cell lung cancer will not continue into phase III, based on phase II data analysis.

Although evidence of clinical activity was seen, there appeared to be an imbalance in toxicity, the company said. BR24 was being conducted by the National Cancer Institute of Canada Clinial Trials Group.